EFPIA response to the EC’s ‘Competitiveness Compass’

3 February 2025

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has welcomed the publication of the Competitiveness Compass by the European Commission (EC) and the recognition of the role that innovation in life sciences can play in reigniting competitiveness in the European Union (EU).

EC President Ursula von der Leydon announced the new roadmap last week at Davos 2025. The EU aims to close the innovation gap by investing in sectors like artificial intelligence (AI), biotechnology and space technology. Specifically, it plans an EU Start-up and Scale-up Strategy to encourage new companies to emerge and flourish.

The EFPIA also said it strongly supports the objective of simplification and coordination of the EU regulatory environment as a key component of the region’s competitiveness.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK